- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT02768467
Buccal Mucosa Healing Trial With Tissue Matrix Placement
A Prospective Randomized Controlled Trial of Buccal Mucosa Donor Site Healing With Tissue Matrix Placement
Prior studies have been performed to understand the optimal way to minimize the morbidity rate of buccal mucosa. While some studies have reported primary closure to be inferior to healing by secondary intention, this appears to be true for large defects greater than 2 cm in width. For small defects for which the wound can be closed without tension, the most recent study has shown improved pain outcomes in the immediate post-operative setting, although no difference is seen long term whether or not the wound was primarily closed. However, for larger defects, standard practice is to allow delayed healing by secondary intention.
The use of Alloderm graft placement for donor site coverage was first described in Armenakas' group. Alloderm is an acellular dermal lattice from human allograft skin. The only study to report the use of Alloderm failed to find a significant improvement in patient outcomes; however, very small defects were included in this study and the control group underwent primary closure, which has been shown to be inferior for large defects. Importantly, no increase in post-operative pain was noted, although there was some increased swelling reported. From experience, patients with moderate and large (>2 cm width) defects following buccal mucosa harvest benefit from Alloderm placement with decreased post-operative pain, more rapid resumption of normal diet and mouth function with no associated increase in morbidity of the procedure. This study aims to determine whether this is a reliable improvement in technique.
This study will clarify how the cheek heals after the buccal mucosa is removed during reconstructive surgery. Subjects will be randomized to either receive tissue collagen matrix or no stitches after the surgery. Subjects will be evaluated up to six months to determine if the outcomes of the tissue matrix graft are better for the subject.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Faktiske)
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiesteder
-
-
New York
-
New York, New York, Forente stater, 10016
- New York University Langone Medical Center
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- >18 years of age
- Male
- Patients with clinically necessary buccal mucosal graft >2 cm
- Patients who are able to present for pre-operative and post-operative evaluations
- Patients who are able to comprehend and read English
Exclusion Criteria:
- History of oral cancer
- Severe cognitive impairments
- Unwilling or unable to follow procedures in protocol
- Contraindicated to participate for any reason
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Dobbelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Eksperimentell: Tissue Matrix Graft Placement
After the buccal mucosa is removed during reconstructive surgery, the wound is covered with an acellular tissue collagen matrix
|
Subject will receive a covering for the wound post buccal mucosa removal.
|
Aktiv komparator: Without stitches
After the buccal mucosa is removed during reconstructive surgery, no stitches will be used for the wound to heal.
|
Subject will not receive stitches post buccal mucosa removal.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Pain Level
Tidsramme: Six months
|
Measured by the Visual Analog Scale
|
Six months
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Time to Normal Eating
Tidsramme: Six Months
|
This is measured by time.
|
Six Months
|
Presence of Swelling
Tidsramme: Six Months
|
This is measured by time
|
Six Months
|
Mouth mobility
Tidsramme: Six Months
|
This is measured by time
|
Six Months
|
Presence of Paresthesia
Tidsramme: Six Months
|
This is measured by time
|
Six Months
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: Lee Zhao, MD, NYU Langone Health
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Andre studie-ID-numre
- 16-00669
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
produkt produsert i og eksportert fra USA
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Tissue Grafts
-
University of LiegeAvsluttetKronisk graft-versus-vert-sykdom | Akutt graft-versus-vert-sykdom | Steroid refraktær graft-versus-vertssykdomBelgia
-
National Cancer Institute (NCI)AvsluttetGraft vs vertssykdom | Graft-versus-vertssykdom | Kronisk graft vs. vertssykdomForente stater
-
H. Lee Moffitt Cancer Center and Research InstituteGateway for Cancer ResearchFullførtGraft vs. vertssykdomForente stater
-
Dana-Farber Cancer InstituteBayer; Genzyme, a Sanofi CompanyFullført
-
Mesoblast, Inc.Quintiles, Inc.FullførtGrad B akutt graft versus vertssykdom | Grad C akutt graft versus vertssykdom | Grad D akutt graft versus vertssykdomForente stater
-
Regimmune CorporationFullførtGraft vs vertssykdom | Graft-versus-vert-sykdom | Akutt-graft-versus-vert-sykdom | Forebygging av aGVHDForente stater
-
Jazz PharmaceuticalsFullførtAkutt-graft-versus-vert-sykdom | Graft-versus-host-sykdomForente stater, Belgia, Storbritannia, Hellas, Tyskland, Spania, Frankrike, Italia, Østerrike, Canada, Bulgaria, Kroatia, Polen, Portugal
-
Rambam Health Care CampusTilbaketrukketFekal mikrobiotatransplantasjon i graft vs. vertssykdomIsrael
-
Grupo Espanol de trasplantes hematopoyeticos y...FullførtKronisk graft-versus-vert-sykdomSpania
-
Novartis PharmaceuticalsFullførtKortikosteroid refraktær akutt graft vs vertssykdomTyskland, Japan, Saudi-Arabia, Tyrkia, Storbritannia, Spania, Canada, Italia, Australia, Østerrike, Frankrike, Korea, Republikken, Hong Kong, Israel, Nederland, Den russiske føderasjonen, Danmark, Hellas, Taiwan, Norge, Tsjekkia, Bu...
Kliniske studier på Tissue Matrix Graft Placement
-
University of Alabama at BirminghamRekrutteringGingival resesjon | Tynn Gingiva | Mangel på keratinisert festet peri-implantat slimhinneForente stater
-
University of LouisvilleFullført
-
William Beaumont HospitalsDePuy SynthesAktiv, ikke rekrutterendeDegenerativ skivesykdom | Lumbal spinal stenose | Lumbal spondylolistese | Lumbal radikulopati | Lumbal platesykdom | Degenerativ spondylolisteseForente stater
-
Synthes USA HQ, Inc.FullførtKranial Dura ReparasjonForente stater